Exploring the role of KCNJ2 in metabolic reprogramming, especially in the context of glucose metabolism, could also uncover new targets for treatment, potentially improving therapeutic outcomes for patients with advanced ccRCC. The gene discussed is KCNJ2; the disease is nonpapillary renal cell carcinoma.